NICE recommends flu drug for “at risk” patients

The National Institute for Clinical Excellence (NICE) recommended this week that zanamivir (Relenza) should be used to treat “at risk” adults when influenza is circulating in the community and if they present within 36 hours of developing symptoms. The institute defines such patients as those with chronic respiratory disease, significant cardiovascular disease, diabetes, or a compromised immune system, and those …